Overview

• Under the agreement, several Pfizer medicines will be priced for Medicaid at the lowest levels paid in other wealthy countries, including for newly launched drugs.
• Pfizer pledged $70 billion for U.S. manufacturing, research and development as part of the arrangement.
• The White House warned of tariffs if other drugmakers refuse similar terms, and Pfizer is the first company to agree after a late‑September deadline set for 17 firms.
• President Donald Trump said patients outside Medicaid would also see lower prices, a benefit he described without providing details.
• The Washington Post first reported the talks, and Pfizer shares rose more than 2 percent following the report.